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Guinea Pigging in Philadelphia 
Roberto Abadie 
On June 16, 2001, the national press first reported the death of Ellen 
Roche, a healthy 24-year-old who volunteered for an asthma study at 
Johns Hopkins University. The story revealed that a few days into the trial 
she felt very sick, was discharged, and sent home. Within some hours 
she checked into the emergency room at a local hospital and fell into a 
coma. Ellen remained in this state until her death a month later. She had 
received $375 for participating in seven to nine sessions as an outpatient 
in the clinical drug study that resulted in her death. 
This tragedy exposed real gaps in our understanding of human sub-
jects in medical research. Although bioethicists have focused on the eth-
ics of paying subjects to test drug safety, less attention has been paid to 
who the healthy paid subjects are, what motivates them, how they make 
decisions about joining a trial, or the effects money has in the way they 
perceive and deal with risk. The pharmaceutical industry is one of the 
most globalized and profitable businesses in the United States. Anthro-
pologists have been exploring—particularly in this last decade—differ-
ent aspects of the industry, from the influence of drug reps on medical 
prescription practices, to the globalization of clinical trials. Yet the par-
ticipation of healthy paid subjects selling their bodies in the first phase 
of drug development has remained all but invisible. 
In 1998, anthropologist Michaela di Leonardo invited scholars to fo-
cus on what she called “exotics at home.” Her intention was to re-center 
anthropological inquiry, shifting the discipline’s emphasis on “the other,” 
often living in remote cultures, to groups living among us. Di Leon-
ardo argued for the need to look at domestic sources of power, wealth, 
and inequality in an attempt to understand how they affect the every-
day lives of numerous groups and institutions that had remained, until 
then, hidden or invisible. My ethnographic research on human subjects 
in pharmaceutical trials is an attempt to respond to Di Leonardo’s call for 
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anthropologists to refocus our selection of research topics and respon-
dents. In The Professional Guinea Pig: Big Pharma and the Risky World of 
Human Subjects (2010), I present findings from ethnographic research 
with “healthy paid subjects” earning a living by testing drug safety in 
Phase I Clinical Trials. This research took place in 2003 and 2004 in Phil-
adelphia— a center for clinical trials conducted by such giant pharma-
ceutical corporations as Merck, AstraZeneca, Pfizer, and Bristol-Meyers 
Squibb. 
I lived with a group of healthy paid subjects in an area of West Phila-
delphia. This group, mainly white men, had a visible “guinea pig” culture, 
with its own professional zine entitled Guinea Pig Zero, a magazine de-
scribing their participation in the drug trials from the perspective and in-
terests of the professional research subjects. Some professional “guinea 
pigs,” also identify as anarchists, holding a very strong view of the phar-
maceutical industry and governmental regulation. 
This tight-knit community of young, radical political activists is located 
just a few blocks from the University of Pennsylvania campus. Guinea pig-
ging, as the practice of selling one’s body to pharma is informally known, 
provides a flexible schedule and a steady income to support a lifestyle that 
includes living in communal housing, usually in squat homes, and free time 
to devote to creative and political interests. Most members of this commu-
nity have at one point or another taken part in this trial economy. 
I was aware that this would be an unusual subpopulation of profes-
sional guinea pigs, who overall tend to be less affluent, less educated, 
and overwhelmingly from minority groups. Still, I felt confident that their 
experiences as professional subjects would provide a window into the 
roles that the social organization of clinical trials and financial compen-
sation play in recruiting, retaining, and controlling trial subjects. I spent 
18 months from mid-2003 to the end of 2004 among them, following 
them to the trials, screenings, and follow-up appointments and witness-
ing their trial preparations and subsequent tribulations. 
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I wanted to understand how much guinea pigs knew about the risks 
they would face and the degree to which they were concerned with 
the risk factor of medical trials. Financial compensation can reach up to 
$400 a day for an in-patient trial, which usually lasts between two to four 
weeks. Some subjects have volunteered in more than 100 trials in the 
course of a few years. A full-time professional subject can enroll in seven 
or eight trials a year, deriving an income close to $20,000. Although at the 
beginning of the trial, healthy subjects sign an Informed Consent Form 
that delineates the trial’s design, goals, and potential risks, I wondered 
how much the promise or prospect of financial gain shapes the subjects’ 
understanding and willingness to take risks. 
I was also concerned that the pharmaceutical industry would use the 
large sums of money to coerce professional guinea pigs both to join the 
trial and to remain in it. 
The Emergence of the “Professional Guinea Pig” 
After drugs are tested on animals, they are tested on a small group of 
humans to make sure they will be safe for human consumption. This is 
called a Phase I Trial. If a drug is proven to be safe for a small group of 
human beings, then it is further tested in much larger groups of humans, 
partly for safety, but mainly for efficacy. These are the Phase II and III Tri-
als. Until 1970, drug safety was tested on prisoners, but concerns about 
their capacity to give ethical, uncoerced consent brought the practice to 
a halt. The pharmaceutical industry stood to lose billions if drugs com-
ing down their research pipelines could not be tested. Pharma started 
offering payments to potential recruits, and initially, unemployed and 
unemployable people, students, artists, part-time workers, and others 
showed up. Some could not withstand the boredom, the discomfort, 
and the dehumanizing treatment, and never showed up again. But some 
stayed and were lured with phone calls, mailed ads, and other recruit-
ing tactics. These subjects became accustomed to the role of trial sub-
jects, and the industry in turn became dependent on professional, de-
pendable, and compliant research subjects. A new profession emerged: 
the professional research subject. 
Some guinea pigs I met in Philadelphia had other low-paying jobs 
on the side as cooks, house painters, construction workers, or bike mes-
sengers, but for most, trials were their only occupation. As one pro-
fessional guinea pig told me, “You become addicted to the trials, to 
the easy money.” They saw themselves not as “paid volunteers,” as the 
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industry refers to them, but as workers performing a strange type of 
work. In fact, that they have been paid to test drug safety has become 
an integral part of the clinical drug trial enterprise in the United States. 
Pharmaceutical companies depend upon paid subjects to test an ever-
increasing number of drugs coming out of their “pipelines.” Many sub-
jects, like Spam, a seasoned guinea pig volunteer and janitor organizer, 
consider bodily pain, boredom, and compliance as the “mild torture 
economy” of trial participation. 
I don’t know, another thing kind of funny too is that the 
manufacturing has been taken off, outside the country, 
so you are not allowed to do things anymore. They call 
it the new economy, the informational economy. And the 
other side of this informational economy is the mild tor-
ture economy—you are not asked to produce or to do 
something anymore, you are being asked to endure some-
thing. So, if you are a guinea pig you are enduring some-
thing, people are doing things to you and you are just en-
during it, you are not actually producing something. I feel 
that I am a worker, but it is not work, it’s like a security 
guard that does not produce nothing, just watches stuff. 
A security guard just gets paid to be bored, it’s about how 
much can you deal with being bored, that’s the real hard 
part of it, the time and discomfort of being there. But it’s 
different when you are in a cleaning job, I am doing some-
thing, but being a guinea pig is just being paid to endure 
something that happens to me, which is weird. It’s a differ-
ent type of activity, I still feel that there is some work in it 
but the nature of work has changed. And I am letting peo-
ple pay me in exchange for the control they have over me. 
A Risky Business 
Professional guinea pigs perceive most trials as being of moderate risk. 
Adverse drug reactions are extremely rare and most subjects have not 
experienced any serious effects even after years of participation, and be-
sides, they reason, the trial is designed as a controlled experiment and 
supervision is constant. They feel that the pharmaceutical industry is do-
ing the right thing, not because the industry cares about the subjects, 
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but because the industry fears lawsuits if something goes wrong. Their 
preferred trials are those that test drugs such as pain killers or gastritis 
drugs that have already been on the market for some time and thus have 
been tested by millions of people, thus presenting only a moderate risk. 
The drugs they perceive as riskier are those that are tested for the first 
time on humans after being tested before only in animals. In the case 
of a new, experimental psychiatric drug, professional guinea pigs would 
see it as presenting the highest risk, something to be avoided if possi-
ble because “it messes up your mind.” 
Robert Helms elaborates why these trials are perceived as high risk 
and something to be avoided at all cost. 
Psychiatric trials are for a couple of reasons very differ-
ent from trials of nonpsychotropic drugs because they in-
volve your mind. You are renting your mind and your body 
at the same time instead of just your body. It is a com-
pletely different economic deal. Secondly, in the psycho-
tropic drug trials, people are writing diseases into exis-
tence. You cannot fake fast heartbeat into existence; you 
cannot make people believe that the heart is beating 
faster. I put a stethoscope onto your chest and check your 
fucking heartbeat, that’s simple. They cannot invent your 
blood pressure but they can invent your depression; they 
can invent your mood. And they can change the interpre-
tation of what you say according to what the drug market 
wants. The marketing department writes the label of the 
drug, not the fucking doctors, the scientists. It is the mar-
keting department. And they also write the disclaimers, 
fight the lawsuits. Blame the disease, not the drug. Like, 
he is getting into middle age, a lot of time on his hands 
and is getting a little raunchy, goes into the psychiatrist 
for a little talk, gets put on Prozac and two weeks later he 
slaughters the whole family with a rifle and blows his own 
brain out. Tell me it is not the fucking Prozac! That is what 
I think, “Fuck you, fuck you.” And it happens over and over 
again, and the lawsuits get buried by companies that put 
[out] a lot of money to quiet people down. 
Still, mindful of these obstacles, the pharmaceutical industry offers 
the highest payment for these types of trials in an attempt to recruit 
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reluctant trial subjects. Almost everybody I encountered during my field-
work admitted that, despite their concerns, they had done at least one 
trial they thought was too risky, enticed by the $5,000 to $10,000 finan-
cial reward. Subjects considered these trials as presenting high risk but 
were tempted to join them because as they put it “the financial gain was 
too good to refuse.” 
The industry has outsourced the daily operation to Contract Research 
Organizations (CROs) which recruit the volunteers, carry out the trial and 
then hand the data to the industry. Since Phase I trials involve a small 
number of volunteers, between 20 and 100, if only one or two drop out 
in the middle of the trial, it compromises the validity of the whole trial. 
To avoid this, the CROs use professional subjects who know what to ex-
pect from the trial when possible and they also use money to make sure 
subjects stay in the trial until the end. If a subject drops out in the mid-
dle of the trial they get a prorated amount. But the bulk of the payment 
is scheduled at the end, usually followed by a bonus for completion to 
encourage participants to complete the study, no matter what. 
Some, including me, might argue that this practice is unethical and 
challenges current standard guidelines governing human subjects re-
search ethics. The promise of financial gain can unduly coerce vulnerable 
research subjects, leading them to participate in trials they might not join 
otherwise. My main concern is that the market recruitment of trial sub-
jects might place “guinea pigs” in danger, not only because of the risks 
they face in particular trials, but also because they ingest a high dose of 
chemicals during their years of trial participation. These chemicals might 
interact many years later with each other, with drugs taken by the patient 
as part of a treatment, or with toxic environmental pollutants. I suggest 
the creation of a centralized registry of Phase I participants to discourage 
them from participating in more than one trial at a time or neglecting to 
wait the mandatory 30-day wash-out period after a trial ends. This rec-
ommendation is not a silver bullet; it will not automatically solve all the 
problems brought by the increasing reliance on paid subjects involved 
in clinical trials research. For example, its implementation couldn’t have 
avoided the death of Ellen Roche, who died after volunteering for only 
a clinical trial. And while this registry would increase the protection for 
paid research subjects, its implementation would also diminish their fi-
nancial gain. For this reason, the professional guinea pigs I have encoun-
tered seem reluctant about this recommendation. Besides, because the 
pharmaceutical industry does not want to jeopardize its ability to recruit 
paid healthy subjects quickly and efficiently, until this date, it has op-
posed the creation of such a registry in the United States. 
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In Europe Big Pharma adopted and supported the creation of such a 
registry after the Parexel incident in 2008, in which research subjects test-
ing an experimental drug were badly injured. This incident revealed that 
research subjects were volunteering in multiple trials at the same time, 
disregarding the wash-out period, and traveling from country to coun-
try in search of trial opportunities. 
After finishing my research, I realized that this recommendation could 
in fact be extended to all phases of clinical trials research in the United 
States, not just the first phase of drug development. A source who man-
ages a CRO recruiting for Clinical Trials Phases II and III informed me 
about something that is cause for great concern. According to this in-
formant, HIV patients often enroll in two trials at the same time, seeking 
to maximize financial gain. These trials involve hundreds or thousands 
of participants and last many years. They do not pay the large amounts 
Phase I trials command. These trials might pay only a few dollars every 
month, sometimes $20 to $30 or so, to encourage participation. Still, for 
poor patients this meager reward seems lucrative. Their trial, designed 
not to treat them but to answer a scientific question about a drug or 
drug regime, may instead be making these patients sicker. As in the case 
of professional guinea pigs doing Phase I Trials, there is no centralized 
registry of their participation that could help track the future health of 
participants. 
In fact, the lack of a centralized registry or the ineffective FDA over-
sight of the participation of human subjects in pharmaceutical research 
signals a deeper problem. Research subjects lie regarding their simul-
taneous participation in different clinical trials to avoid the mandatory 
wash-out period, and they lie about other things that might exclude them 
from the trials. In turn, Big Pharma pretends that their trial subjects are 
carefully recruited and monitored and that the trials’ outcomes are valid 
and unbiased. As such, consumers cannot be sure that the data a partic-
ular trial produces have not been obfuscated by the surreptitious par-
ticipation of some subjects in another trial, or by the subjects’ neglect of 
the mandatory 30-day wash-out period. Thus the professionalization of 
research subjects in the first phase of trials research can endanger not 
only participants but can also challenge the validity of the trial results. 
The process is so fraught with manipulation and deceit that as a result 
we cannot be sure which drugs work and which ones do not. As some 
professional guinea pigs reminded me, they are willing guinea pigs, but 
the consumers might end up as unwilling guinea pigs, forced to con-
sume drugs that have not been sufficiently or adequately tested. The lack 
of control and oversight of Phase I Trials and in subsequent phases of 
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drug development might not only endanger professional research sub-
jects and trial participants, but might also compromise the public health 
and well-being of us all. 
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